Assess whether to resubmit, meet, or pause the program (fe7c91)

SITUATION A CMO 483 that maps to the NDA CMC module put CMC comparability package for a site change in front of pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / Clinical and Evidence Strategy close is to resubmit, meet, or from CMC comparability package for a site change, and the live options are To resubmit, meet,, Pause the program.

DECISION Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose To resubmit, meet, / Pause the program using CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. CMC comparability package for a site change reads as To resubmit, meet, once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population. 2. CMC comparability package for a site change is closer to Pause the program after a CMO 483 that maps to the NDA CMC module; To resubmit, meet, would over-claim this Clinical and Evidence Strategy extract. 3. A dual reading is still live in CMC comparability package for a site change for pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan. 4. CMC comparability package for a site change is missing the fact pharmacovigilance medical reviewer needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether CMC comparability package for a site change supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module). The follow-on Clinical and Evidence Strategy action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in CMC comparability package for a site change, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan